Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04349761 · ClinicalTrials.gov registry record · Phase 1
Single Ascending-dose Study to Evaluate Safety, Tolerability, and PK of MYMD1 in Healthy Male Adult Subjects
A Phase 1 study, sponsored by TNF Pharmaceuticals.
- Completed
- Registry status
- Phase 1
- Development phase
- 40
- Enrollment target
NCT04349761 is a Phase 1 study that has completed, run by TNF Pharmaceuticals. The registered enrollment target is 40 participants.
The verdict
NCT04349761, a Phase 1 study, has completed, sponsored by TNF Pharmaceuticals.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 40 participants
- Enrollment target
Study Summary
Double-blind, placebo-controlled, First-in-Human, single ascending-dose study. Approximately 40 healthy adult male subjects will be given a single capsule of MYMD1 to determine its safety, how well it is tolerated, how the body acts on the experimental drug, and how the experimental drug acts on the body. This will be based on blood and urine sample analysis and other physical measurements.
Interventions
- DRUG Placebo
- DRUG MyMD1
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 40 participants |
| Start Date | 2019-06-11 |
| Est. Completion | 2019-12-30 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04349761
The ClinicalTrials.gov registry entry for NCT04349761 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 40 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is TNF Pharmaceuticals, which has 3 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT04349761 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT04349761 about?
NCT04349761 is a clinical study titled "Single Ascending-dose Study to Evaluate Safety, Tolerability, and PK of MYMD1 in Healthy Male Adult Subjects". Double-blind, placebo-controlled, First-in-Human, single ascending-dose study. Approximately 40 healthy adult male subjects will be given a single capsule of MYMD1 to determine its safety, how well it is tolerated, how the body acts on the experimental drug, and how the experimental drug acts on the...
What is the current status of trial NCT04349761?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 40 participants. The study started on 2019-06-11. Estimated completion is 2019-12-30.
What interventions are being tested in trial NCT04349761?
The interventions under investigation include: Placebo (DRUG), MyMD1 (DRUG).
Who is sponsoring clinical trial NCT04349761?
This trial is sponsored by TNF Pharmaceuticals, which has 3 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.